Vyome Holdings, Inc
corporate_fare Company Profile
Vyome Holdings, Inc (NASDAQ:HIND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for HIND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for HIND spans 10-Q, 8-K, PRE 14A, 10-K.
Recent high-impact activity:
- Vyome Q3 Loss Nearly Doubles Analyst Estimates as Revenue Misses Zero Bar
- Vyome Q3 Loss Narrows to $930K; Material Weaknesses Persist, FDA Seeks More VT-1953 Data
- Vyome Secures USPTO Notice of Allowance for VT-1908 Ocular Inflammation Patent
- Vyome Posts Q2 Loss, FDA Feedback on VT-1953, and JAK Inhibitor Deal
- Vyome Q2 Loss Widens to $719K; FDA Seeks More Data on VT-1953
Financial Snapshot
Short Interest & Short Volume
1.58 days to coverFINRA reported short interest of 18,468 shares in HIND as of the October 30, 2026 settlement, a 10.7% decrease from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 28.7% of HIND volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.